Ignite Creation Date:
2025-12-24 @ 2:35 PM
Ignite Modification Date:
2026-01-06 @ 11:11 PM
Study NCT ID:
NCT04649359
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-02
First Post:
2020-11-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Sponsor:
Pfizer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-02-02
Start Date Type:
ACTUAL
Primary Completion Date:
2022-06-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2020-11-06
First Submit QC Date:
None
Study First Post Date:
2020-12-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-06-15
Results First Submit QC Date:
None
Results First Post Date:
2023-10-25
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-17
Last Update Post Date:
2025-12-02
Last Update Post Date Type:
ESTIMATED